Intrathecal Rosiglitazone Acts at Peroxisome Proliferator-Activated Receptor-γ to Rapidly Inhibit Neuropathic Pain in Rats

Journal of Pain

Volumn 9, Issue 7, 2008, Pages 639-649

  Churi, Sajay B ^a   Abdel Aleem, Omar S ^a   Tumber, Kiranjeet K ^a   Scuderi Porter, Heather ^a   Taylor, Bradley K ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

16 deoxy prostaglandin J2; Allodynia; hyperalgesia; pioglitazone; rat; spared nerve injury

Indexed keywords

15 DEOXYPROSTAGLANDIN J2; BISPHENOL A GLYCIDYL ETHER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROSTAGLANDIN J2; ROSIGLITAZONE;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; ELECTROPHORETIC MOBILITY; GENE EXPRESSION REGULATION; HYPERSENSITIVITY; LIGAND BINDING; MALE; MOTOR COORDINATION; NEUROPATHIC PAIN; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; SCIATIC NERVE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPOXY COMPOUNDS; GENE EXPRESSION; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MALE; MOTOR ACTIVITY; NEURALGIA; PPAR GAMMA; PROSTAGLANDIN D2; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCIATIC NERVE; SPINAL CORD; THIAZOLIDINEDIONES;

EID: 45549087654     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2008.02.002     Document Type: Article

References (43)

1. Abdelrahman M., Sivarajah A., and Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65 (2005) 772-781
2. Berger J., Akiyama T., and Meinke P. PPAR-s: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 26 (2005) 244-251
3. Bernardo A.M.L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12 (2006) 93-109
4. Bishop-Bailey D., Hla T., and Warner T.D. Bisphenol A diglycidyl ether (BADGE) is a PPAR-gamma agonist in an ECV304 cell line. Br J Pharmacol 131 (2000) 651-654
5. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
6. Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., and Clark J.B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem 70 (1998) 1366-1375
7. Decosterd I., and Woolf C.J. Spared nerve injury: An animal model of persistent peripheral neuropathic pain. Pain 87 (2000) 149-158
8. Dehmer T., Heneka M.T., Sastre M., Dichgans J., and Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88 (2004) 494-501
9. DeLeo J.A., Tanga F.Y., and Tawfik V.L. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 10 (2004) 40-52
10. Fehlberg S., Trautwein S., Goke A., and Goke R. Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners. Biochem J 362 (2002) 573-578
11. Gardner O.S., Dewar B.J., and Graves L.M. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol 68 (2005) 933-941
12. Gilron I., Bailey J.M., Tu D., Holden R.R., Weaver D.F., and Houlden R.L. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 (2005) 1324-1334
13. Heneka M.T., Landreth G.E., and Feinstein D.L. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann Neurol 49 (2001) 276
14. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., and Landreth G.E. Acute treatment with the PPAR-gamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
15. Kota B.P.H.T., and Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharm Res 51 (2005) 85-94
16. Lehrke M.L.M. The many faces of PPAR-gamma. Cell 123 (2005) 993-999
17. Losel R.M., Falkenstein E., Feuring M., Schultz A., Tillmann H.C., Rossol-Haseroth K., and Wehling M. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83 (2003) 965-1016
18. LoVerme J.R.R., La Rana G., Fu J., Farthing J., Mattace-Raso G., Meli R., Hohmann A., Calignano A., and Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319 (2006) 1051-1061
19. Malkmus S.A., and Yaksh T.L. Intrathecal catheterization and drug delivery in the rat. Methods Mol Med 99 (2004) 109-121
20. Marchand F., Perretti M., and McMahon S.B. Role of the immune system in chronic pain. Nat Rev Neurosci 6 (2005) 521-532
21. Martens F.M., Visseren F.L., Lemay J., de Koning E.J., and Rabelink T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62 (2002) 1463-1480
22. Michalik L., and Wahli W. Involvement of PPAR-nuclear receptors in tissue injury and wound repair. J Clin Invest 116 (2006) 598-606
23. Moalem G., and Tracey D.J. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 51 (2006) 240-264
24. Moraes L.A., Piqueras L., and Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110 (2006) 371-385
25. Moreno S., Farioli-Vecchioli S., and Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004) 131-145
26. Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., and Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor (gamma) agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. Park SW YJ. J Pharmacol Exp Ther 320 (2007) 1002-1012
27. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1997), Academic Press, Inc, Orlando, FL
28. Proescholdt M.G., Hutto B., Brady L.S., and Herkenham M. Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer [14C]inulin in rat. Neuroscience 95 (2000) 577-592
29. Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schurmann B., Zimmer A., and Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 25 (2005) 7805-7812
30. Soares A.F., Nosjean O., Cozzone D., D'Orazio D., Becchi M., Guichardant M., Ferry G., Boutin J.A., Lagarde M., and Geloen A. Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPAR-gamma. Biochem Biophys Res Commun 337 (2005) 521-525
31. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
32. Sundararajan S., Jiang Q., Heneka M., and Landreth G. PPAR-gamma as a therapeutic target in central nervous system diseases. Neurochem Int 49 (2006) 136-144
33. Taiwo O.B., and Taylor B.K. Antihyperalgesic effects of intrathecal neuropeptide Y during inflammation are mediated by Y1 receptors. Pain 96 (2002) 353-363
34. Tan N.S., Michalik L., Desvergne B., and Wahli W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol 93 (2005) 99-105
35. Taylor B.K., Holloway D., and Printz M.P. A unique central cholinergic deficit in the spontaneously hypertensive rat: Physostigmine reveals a bradycardia associated with sensory stimulation. J Pharmacol Exp Ther 268 (1994) 1081-1090
36. Taylor B.K., Kriedt C., Nagalingam S., Dadia N., and Badr M. Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflamm Res 54 (2005) 235-242
37. Yang C.B., Krishnan S., and Badr M. Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Taylor BK DN. Inflammation 26 (2002) 121-127
38. van Neerven S., and Mey J. RAR/RXR and PPAR-/RXR signaling in spinal cord injury. PPAR Res 2007 (2007) 29275
39. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., and Sundararajan S. Altered PPAR-gamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 24 (2006) 1653-1663
40. Wieseler-Frank J., Maier S.F., and Watkins L.R. Central proinflammatory cytokines and pain enhancement. Neurosignals 14 (2005) 166-174
41. Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., and Spiegelman B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. Wright HM CC. J Biol Chem 275 (2000) 1873-1877
42. Yezierski R.P. Pain following spinal cord injury: Pathophysiology and central mechanisms. Prog Brain Res 129 (2000) 429-449
43. Zhelyaznik N., and Mey J. Regulation of retinoic acid receptors alpha, beta and retinoid X receptor alpha after sciatic nerve injury. Neuroscience 141 (2006) 1761-1774